5 completed, 1 terminated, 1 unknown, 1 withdrawn. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Schnitzler Syndrome: new trials by email Literature Review of Schnitzler Syndrome trials Research Report on Schnitzler Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome 80 mg RPH-104, Placebo - Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder) | Phase 2 | Withdrawn | R-Pharm Overseas, Inc. | 2023-05-01 | 2024-11-15 | |
| Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome dapansutrile - Schnitzler Syndrome | Phase 2 | Terminated | Olatec Therapeutics, Inc. | 2 | 2018-05-15 | 2024-02-02 |
| Tocilizumab in Patients With Schnitzler's Syndrome Tocilizumab - Schnitzler's Syndrome | Phase 2 | Completed | Karoline Krause | 8 | 2017-07-19 | 2020-02-17 |
| Ilaris® Effects in Schnitzler Syndrome (ILESCH) Canakinumab, Placebo - Schnitzler Syndrome | Phase 2 | Completed | Charite University, Berlin, Germany | 20 | 2011-07-01 | 2018-07-17 |
| Ilaris (Canakinumab) in the Schnitzler Syndrome Ilaris - Schnitzler Syndrome | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 1 | 2011-05-01 | 2019-07-05 |
| Efficacy and Safety of Canakinumab in Schnitzler Syndrome Canakinumab - Schnitzler Syndrome | Phase 2 | Completed | Radboud University Medical Center | 8 | 2011-01-01 | 2012-05-24 |
| Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) rilonacept - Muckle-Wells Syndrome, Schnitzler Syndrome | Phase 2 | Completed | Charite University, Berlin, Germany | 10 | 2009-01-01 | 2012-05-31 |
| The Efficacy and Safety of ITF2357 in AIS ITF2357 - Autoinflammatory Syndromes, HIDS | Phase 2 | Unknown | Radboud University Medical Center | 20 | 2006-09-01 | 2007-03-01 |
Cryopyrin-Associated Periodic Syndromes (1) · Paraproteinemias (1)
Immune System Diseases (8) · Immunoproliferative Disorders (8) · Monoclonal Gammopathy of Undetermined Significance (8) · Paraproteinemias (7) · Blood Protein Disorders (1) · Chronic Disease (1) · Chronic Inducible Urticaria (1) · Chronic Urticaria (1) · Cold Urticaria (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hereditary Autoinflammatory Diseases (1)
canakinumab (3) · dapansutrile (1) · givinostat hydrochloride (1) · rilonacept (1) · tocilizumab (1)
Charite University, Berlin, Germany (2) · Radboud University Medical Center (2) · Karoline Krause (1) · Olatec Therapeutics, Inc. (1) · R-Pharm Overseas, Inc. (1) · Universitaire Ziekenhuizen KU Leuven (1)
Germany (3) · Netherlands (3) · Belgium (1) · United States (1)
Karoline Krause, MD (2) · Anna Simon, MD PhD (1) · Curt Scribner, MD (1) · Marcus Maurer, MD (1) · Steven Vanderschueren, MD, PhD (1) · Yan Lavrovsky (1)